All 1 tracked stories fall under one category: markets. S&P Global BMI Index is most often covered alongside Atrium Therapeutics, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about S&P Global BMI Index
All 1 tracked stories fall under one category: markets. S&P Global BMI Index is most often covered alongside Atrium Therapeutics, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6 in the same window. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. S&P Global BMI Index appears in 1 tracked Finance story from March 3, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering S&P Global BMI Index. Shared-story counts are live from our verified record — not editorial picks.
Avidity Biosciences (RNAM) has been removed from the S&P Global BMI and S&P TMI indices, effective March 2026. This technical deletion follows a major strategic milestone involving a deal closure with Novartis, signaling a period of significant structural transition for the biotech firm.
S&P Global BMI Index is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.